Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2015

CELLULAR BIOMEDICINE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36498		86-1032927
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

19925 Stevens Creek Blvd., Suite 100 Cupertino, California		95014
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (408) 973-7884

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 20, 2015, Cellular Biomedicine Group, Inc. (the “Company”) completed its 2015 annual meeting of stockholders (the "Annual Meeting"). The number of shares of common stock entitled to vote at the Annual Meeting was 11,620,165 shares. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 8,271,566 shares. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and Wen Tao (Steve) Liu, Nadir Patel and Wei (William) Cao were elected “Class III” directors.

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

(i) To elect three (3) “Class III” directors, each of whom will be elected for a term of three years, or until the election and qualification of their successors.

Nominee	Shares Voted For	Shares Withheld
Wen Tao (Steve) Liu	7,849,055	422,511
Nadir Patel	7,919,246	352,320
Wei (William) Cao	7,046,621	1,224,945

(ii) To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.

Shares Voted For		Shares Voted Against		Shares Abstaining
7,895,988		851		374,727

Item 7.01 Regulation FD Disclosure.

On November 23, 2015, Cellular Biomedicine Group, Inc. (the “Company”) issued a press release announcing the results of the Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated November 23, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cellular Biomedicine Group, Inc.

Date: November 30, 2015	By:	/s/ Bizuo (Tony) Liu
		Bizuo (Tony) Liu
		Chief Financial Officer

Exhibit 99.1

Cellular Biomedicine Group Announces Voting Results of 2015 Annual General Meeting

SHANGHAI, China and CUPERTINO, Calif., November 23, 2015 /GlobeNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced the voting results of its 2015 Annual General Meeting (the “Annual Meeting”) held on November 20, 2015 in Cupertino, California. Approximately 71% of the Company’s outstanding shares were represented at the 2015 Annual Meeting.

The following business items were approved at the Annual Meeting:

●	Re-election of Wen Tao (Steve) Liu, Wei (William) Cao and Nadir Patel to the Company’s Board of Directors for a new Class III term, to serve for a term of three years or until the election and qualification of their successors.

●	Ratification of the appointment of BDO China Shu Lun Pan Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.

“We appreciate the high level of shareholder participation and support for this year’s Annual Meeting and the votes in accordance with management’s recommendations. Our management will continue to strive to maximize shareholder value and to realize our mission to deliver evolutionary science in order to serve large patient populations,” said Tony (Bizuo) Liu, Chief Financial Officer of Cellular Biomedicine Group.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our GMP facilities in China, consisting of nine independent cell production lines, are designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contacts:

Sarah Kelly

Director of Corporate Communications, CBMG

+1 408-973-7884

sarah.kelly@cellbiomedgroup.com

Vivian Chen

Managing Director Investor Relations, Grayling

+1 347 481-3711

vivian.chen@grayling.com